|

EB-DART-NK01 (DLL3/CD56 CAR-NK cells) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Relapsed/Refractory SCLC1
  • Small Cell Lung Cancer (SCLC)1
  • SCLC,Extensive Stage1
  • Lung Cancer1
  • Cancer1

Other1 trial

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.